Anthem GLP-1 Prior Authorization Guide: Wegovy, Zepbound, Saxenda and Foundayo Criteria

Anthem is the Blue Cross Blue Shield licensee in 14 states under its parent company, Elevance Health. For GLP-1 weight-loss drugs on its commercial pharmacy benefit, Anthem reviews prior authorization requests against drug-specific clinical criteria that the CarelonRx Pharmacy and Therapeutics Committee approves and that Anthem links from its public drug lists. We read the current Wegovy, Zepbound, Saxenda and Foundayo criteria (revised September 16, 2026), Anthem's commercial drug lists, and its Medicaid and Medicare provider notices. The short version: if your plan includes weight-loss drugs, Anthem wants six months in a supervised diet and exercise program before the first approval (unless your BMI is 40 or higher, or you have advanced heart failure or moderate-to-severe sleep apnea), approves 16 to 36 weeks at a time, and renews only with documented 5% weight loss. Whether your plan includes weight-loss drugs at all is a separate question, and your plan documents answer it.

TL;DR — Anthem GLP-1 coverage at a glance

For a commercially-insured Anthem member (employer-group plan, not Medicaid and not Medicare Advantage):

• Wegovy: listed on Anthem's commercial drug lists with prior authorization, a quantity limit and a benefit-exclusion flag, which means it is covered only if your plan includes weight-loss drugs. You need a BMI of 30 or higher, or 27 or higher with a weight-related condition, plus six months in a supervised diet and exercise program. The six months are waived at BMI 40 or higher, with class III or IV heart failure, or with moderate-to-severe sleep apnea. The first approval lasts 28 weeks. Anthem has separate Wegovy criteria for heart-attack and stroke risk reduction and for MASH.
• Zepbound: the same criteria as Wegovy, with a 36-week first approval. Anthem's criteria do not make you try Wegovy first, and Zepbound sits on the same tier as Wegovy on the national drug list we checked.
• Saxenda: the same criteria, a 16-week first approval, and renewal at 5% weight loss. On the Virginia National Drug List, brand Saxenda is non-formulary, while generic liraglutide for weight management is Tier 1 with prior authorization.
• Ozempic / Mounjaro: covered for type 2 diabetes, with prior authorization for new starts. Anthem's diabetes criteria rule out using them alongside Wegovy, Zepbound, Saxenda or Foundayo, so they are not a route to weight-loss coverage without diabetes.
• Foundayo: Anthem has published criteria with the same structure as Zepbound and a six-month first approval. It is Tier 2 with prior authorization on the Virginia National Drug List.
• Self-funded employers: an employer that self-funds its plan can leave weight-loss drugs out entirely. Your plan documents decide that, not the drug list.

Anthem corporate structure: Elevance Health, 14 state Blues plans, and CarelonRx

Understanding the corporate structure is prerequisite to understanding why PA criteria vary:

• Elevance Health is the publicly traded parent company (NYSE: ELV). It rebranded from Anthem, Inc. in 2022. It operates approximately 46 million medical member lives across commercial, Medicare Advantage, and Medicaid business lines.
• Anthem state Blue Cross Blue Shield subsidiaries: Elevance Health / Anthem is the licensed BCBS operator in 14 states: California (Anthem Blue Cross), Colorado (Anthem Blue Cross Blue Shield), Connecticut (Anthem Health Plans), Georgia (Blue Cross Blue Shield Healthcare Plan of Georgia), Indiana (Anthem Blue Cross and Blue Shield), Kentucky (Anthem Health Plans of Kentucky), Maine (Anthem Health Plans of Maine), Missouri (Anthem Blue Cross and Blue Shield), Nevada (Anthem Blue Cross and Blue Shield), New Hampshire (Anthem Health Plans of New Hampshire), New York (Anthem Blue Cross and Blue Shield in 17 southeastern counties, formerly Empire BlueCross BlueShield), Ohio (Community Insurance Company / Anthem), Virginia (Anthem Blue Cross and Blue Shield), and Wisconsin (Anthem Blue Cross and Blue Shield). Each subsidiary issues its own subscriber agreements and may apply its own PA criteria, prior authorization forms, and step-therapy requirements, even though the drug-list clinical criteria are shared.
• CarelonRx: Anthem's own pharmacy benefit manager (PBM), rebranded from IngenioRx in 2023 and a direct subsidiary of Elevance Health. CarelonRx's Pharmacy and Therapeutics Committee approves the clinical criteria that Anthem links from its drug lists, and each drug list sets the tier, prior authorization, quantity limit and benefit-exclusion flags. See the Aetna GLP-1 PA guide for how a different insurer and PBM handle the same drugs.
• Anthem Medicaid: Anthem runs Medicaid managed-care plans in several states under state-specific names, such as Anthem HealthKeepers Plus in Virginia. Medicaid coverage follows each state's rules and Preferred Drug List, not Anthem's commercial criteria. See the State-Specific Variation and Excluded Plans sections below.
• Member count overlap: the ~46M Anthem figure overlaps materially with the BCBSA aggregate member count (~119M) because Anthem IS the Blue Cross licensee in 14 states — these populations should not be summed.

Primary source: Anthem's commercial clinical criteria (revised September 16, 2026)

Anthem does not publish its GLP-1 weight-loss criteria as a numbered “CC” document. Its CC series covers drugs given under the medical benefit, and Anthem says the criteria for oral and self-injected drugs are in its searchable drug lists. Look up a drug there and its “Clinical Criteria” link opens the current document. We read the Wegovy, Zepbound, Saxenda and Foundayo documents (all revised September 16, 2026) and found the same documents linked from both the Virginia National and Indiana Essential drug lists.^{[1][9][10][11]}

For adults, the chronic weight management criteria are the same for Wegovy, Zepbound, Saxenda and Foundayo:

• Benefit check first: the Wegovy and Saxenda criteria apply “when member's benefit covers weight loss drugs and requires prior authorization,” and Anthem's drug lists flag all four drugs as a possible benefit exclusion.
• BMI: 30 or higher, or 27 or higher with at least one of these: high blood pressure (treated, or 130/80 or above), type 2 diabetes, dyslipidemia (treated, or LDL of 160 or more, triglycerides of 150 or more, or low HDL), obstructive sleep apnea, or cardiovascular disease. The BMI has to be documented within 90 days of the request.
• Lifestyle program: at least six months in a provider-supervised program before the request, with a calorie deficit of about 500 kcal a day, 150 minutes of exercise a week (unless a clinical limitation rules it out), and less than 5% weight loss despite both. The six months are waived for a BMI of 40 or higher, NYHA class III or IV heart failure, or moderate-to-severe obstructive sleep apnea (AHI of 15 or higher). Everyone has to stay in a supervised program during treatment, cannot take two weight-loss drugs at once, and must be counseled on risks and realistic expectations.
• Approval length and renewal: first approvals run 28 weeks for Wegovy, 36 weeks for Zepbound, 16 weeks for Saxenda and 6 months for Foundayo. Renewals last one year and need documented 5% weight loss, achieved or maintained, recorded within 90 days of each renewal request. Teens on Wegovy or Saxenda renew with a reduction of more than 4% from their starting BMI.
• Never approved: a BMI under 18.5, a personal or family history of medullary thyroid carcinoma or MEN 2, or use together with another GLP-1 drug.

Prior-authorization criteria by drug

Wegovy PA criteria (Anthem commercial)

Wegovy (semaglutide injection, including the 7.2 mg dose, and Wegovy tablets) is Tier 2 with prior authorization, a quantity limit and a benefit-exclusion flag on the Virginia National Drug List.^[10] For weight management it follows the adult criteria above, with a 28-week first approval.^[1] Teens 12 to 17 can qualify for the injection with a BMI at or above the 95th percentile for their age and sex, after six months of family nutrition and behavior counseling.

Cardiovascular risk-reduction pathway: Anthem has separate Wegovy criteria for adults who have had a heart attack or stroke, or who have symptomatic peripheral artery disease. You need a BMI of 27 or higher (documented within 90 days), an HbA1c below 6.5%, and current guideline-directed treatment: an antiplatelet or anticoagulant, a high-intensity or maximum-tolerated statin, blood-pressure treatment, and a beta blocker after a heart attack, unless one of these is not tolerated or not warranted. This pathway has no six-month diet-program requirement, and approval lasts one year.^[1] For the underlying evidence, see our SELECT trial cardiovascular benefits article.

MASH pathway: Anthem's Wegovy criteria also cover adults with noncirrhotic MASH and moderate-to-advanced (F2 to F3) fibrosis, confirmed by FibroScan or MR elastography within the past year or by a liver biopsy within three years, after a supervised lifestyle program did not work well enough. Approval lasts one year. Renewal requires improvement in the NAFLD activity score or in fibrosis, without progression to cirrhosis.^[1] California's Medi-Cal notice separately keeps Wegovy reviewable for MASH or cardiovascular disease after the January 1, 2026 weight-loss removal (see the California section).

Quantity limits: Anthem's drug-list search shows 4 pens per 28 days for Wegovy 2.4 mg, 1 pen per week for Zepbound, 3 mg a day for liraglutide, and 1 tablet a day for Foundayo.^[10] Limits can differ from one drug list to another, so check the list your plan uses.

Anthem commercial criteria for Wegovy in chronic weight management (summary): the criteria apply “when member's benefit covers weight loss drugs and requires prior authorization.” Adults need a BMI of 30 or higher, or 27 or higher with a listed weight-related condition. They also need six months of supervised calorie and exercise goals that did not produce 5% weight loss, unless their BMI is 40 or higher or they have class III or IV heart failure or moderate-to-severe sleep apnea. Renewal requires a maintained 5% weight loss.
Source: Anthem / CarelonRx clinical criteria for Wegovy (semaglutide), revised September 16, 2026, linked from Anthem's commercial drug-list search. This is a summary, not the verbatim text.

Zepbound PA criteria (Anthem commercial)

Zepbound (the tirzepatide single-dose pen) is Tier 2 on the Virginia National Drug List, with prior authorization, a limit of one pen a week, and a benefit-exclusion flag.^[10] Anthem's Zepbound criteria use the same adult requirements as Wegovy, with a 36-week first approval and one-year renewals at 5% maintained weight loss.^[9]

No Wegovy-first step: none of Anthem's published criteria requires you to try Wegovy before Zepbound. On the Virginia National Drug List (current as of October 1, 2026), Wegovy and Zepbound sit on the same tier with prior authorization, quantity limits and a benefit-exclusion flag, and neither carries a step-therapy flag. California goes the other way: since January 1, 2026, Wegovy has been non-formulary on Anthem's California commercial lists while Zepbound is Tier 3.^[10][13] Your own plan can still differ, so check its drug list.

Sleep apnea: the FDA approved Zepbound in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. Anthem's commercial Zepbound criteria have no separate sleep-apnea pathway. Moderate-to-severe sleep apnea (AHI of 15 or higher) waives the six-month diet-program requirement instead, and the BMI criteria still apply.^[9] For the evidence, see our SURMOUNT-OSA tirzepatide / sleep apnea article.

Continuation: after the 36-week first approval, renewals last one year. Each one needs documented 5% weight loss, achieved or maintained and recorded within 90 days of the request, plus continued participation in a supervised lifestyle program.^[9]

Saxenda PA criteria (Anthem commercial)

Saxenda (liraglutide 3 mg, daily injection) follows the same adult criteria, with a 16-week first approval and one-year renewals at 5% maintained weight loss.^[11] On the Virginia National Drug List, brand Saxenda is non-formulary, and generic liraglutide for weight management is Tier 1 with prior authorization, a 3 mg daily limit and a benefit-exclusion flag.^[10]

Teens 12 to 17 can qualify if they weigh more than 60 kg and have a BMI equivalent to an adult BMI of 30, after six months of family nutrition and behavior counseling. Their first approval lasts 20 weeks, and renewal needs a reduction of more than 4% from their starting BMI.^[11]

Saxenda is excluded from the CMS Medicare GLP-1 Bridge. Anthem Medicare Advantage members who want covered weight-loss GLP-1 access through the bridge after 07/01/2026 must use Wegovy, Zepbound KwikPen, or Foundayo.

Foundayo (orforglipron) PA criteria (Anthem commercial)

Foundayo (orforglipron), which the FDA approved on April 1, 2026, has its own Anthem criteria with the same adult requirements as Zepbound and a six-month first approval.^[12] It is Tier 2 on the Virginia National Drug List, with prior authorization, a limit of one tablet a day, and a benefit-exclusion flag.^[10]

Renewals last one year and need documented 5% weight loss, achieved or maintained. As with the other drugs, Foundayo cannot be combined with another GLP-1.^[12]

For Anthem Medicare Advantage members: Foundayo is included in the CMS Medicare GLP-1 Bridge, with a $50 copay for eligible enrollees, beginning July 1, 2026 — see the Medicare section below.

For detailed evidence on orforglipron's mechanism and trial data, see our Foundayo vs Wegovy vs Zepbound comparison.

Off-label T2D drugs (Ozempic, Mounjaro) for weight loss — Anthem's stance

Ozempic (semaglutide 0.5–2 mg, weekly injection) and Mounjaro (tirzepatide 2.5–15 mg, weekly injection) are FDA-approved exclusively for type 2 diabetes. Anthem's commercial criteria for them require a verified type 2 diabetes diagnosis, so a request for weight loss alone does not meet the criteria.

Anthem's commercial diabetes GLP-1 criteria (revised October 27, 2026) approve Ozempic and Mounjaro for one year when:^[14]

• Type 2 diabetes is verified by an A1C of 6.5% or higher, a fasting glucose of 126 or higher, a 2-hour glucose tolerance result of 200 or higher, or diabetes symptoms with a random glucose of 200 or higher.
• And one of these applies: metformin was tried without enough effect or was not tolerated, you cannot take metformin, you have a history of atherosclerotic cardiovascular disease (such as a heart attack, stroke, angina or peripheral artery disease), or, for Ozempic injection, you have type 2 diabetes with chronic kidney disease.
• Renewal only re-confirms the type 2 diabetes diagnosis. The drug list marks these drugs “Prior Authorization - New Starts.”

Anthem's diabetes criteria also bar using these drugs together with Wegovy, Zepbound, Saxenda or Foundayo. If you want weight-loss coverage without type 2 diabetes, the weight-loss criteria above are the route to use.

Step-therapy requirements

Anthem's published criteria contain one real “step” for weight-loss drugs, and it is not another drug. It is the six-month supervised lifestyle program. Here is what each drug requires:

What this means in practice: under Anthem's published criteria, you do not have to fail Wegovy to get Zepbound. What you do need is chart documentation of the six-month program: the dates, the calorie and exercise targets, and your starting and ending weights showing less than 5% loss. If your BMI is 40 or higher, or you have class III or IV heart failure or moderate-to-severe sleep apnea, say so in the request, because each of those waives the six months. Some plans and state lists work differently. If your own plan's drug list shows a step-therapy flag, Anthem has a step-therapy exception request.

State-specific PA variation — CA, VA, IN, NY, OH, GA

Because Anthem operates as 14 separate state Blue Cross subsidiaries, PA criteria can — and do — differ between states. Anthem's commercial criteria documents are shared across states, but tiers differ by drug list (California is the clearest example), and Medicaid is a separate program in every state. Below are the two states with published Anthem Medicaid documents, plus shorter notes for four high-volume states.

California (Anthem Blue Cross Medi-Cal)

Anthem Blue Cross is a Medi-Cal managed care plan in California. For Medi-Cal members (not commercial), the operative coverage changed effective January 1, 2026: Wegovy, Zepbound, and Saxenda were removed from Anthem Medi-Cal coverage when prescribed for weight-loss indications, per the Anthem Blue Cross provider notice of November 14, 2025. The removal came from Medi-Cal Rx itself, so Health Net's Medi-Cal members lost the same coverage on the same date.

Anthem Blue Cross (California Medi-Cal), “GLP-1 Coverage Considerations,” November 14, 2025, in summary: Wegovy, Zepbound and Saxenda leave the Medi-Cal Rx Contract Drugs List on January 1, 2026. Claims for them deny regardless of indication, and earlier approvals expire. Prior authorization requests are still considered for Wegovy used for noncirrhotic MASH or cardiovascular disease and for Zepbound used for obstructive sleep apnea. Requests for members under 21 are reviewed for medical necessity under the federal EPSDT benefit.
Source: providers.anthem.com/docs/gpp/california-provider/CA_MMP_GLP1Coverage.pdf. California moved its outpatient pharmacy benefit out of managed care into the statewide Medi-Cal Rx program on January 1, 2022, so this change comes from the state program rather than from Anthem's own formulary. See our California Medi-Cal GLP-1 coverage article for the state-level sources.

California commercial (Anthem Blue Cross): the Medi-Cal change does not apply to commercial members, but Anthem's California commercial lists changed too. Effective January 1, 2026, Wegovy and Saxenda moved to non-formulary and Zepbound moved from Tier 2 to Tier 3 on Anthem's California CDI and DMHC National and Essential drug lists.^[13] Where a plan covers weight-loss drugs, the same Anthem clinical criteria apply, and a non-formulary drug can be requested through Anthem's formulary exception process.

Virginia (Anthem HealthKeepers Plus Medicaid)

The Anthem HealthKeepers Plus Virginia Medicaid Weight-Loss Management PA Form (available at providers.anthem.com/docs/gpp/VA_CAID_WeightLossMgmtPAForm.pdf ) sets out the Virginia Medicaid PA criteria — which are much stricter than Anthem's commercial criteria:

Virginia Medicaid Weight Loss Management PA Form (September 2026 version), GLP-1 criteria in summary: a BMI above 40 with no risk factors, or above 37 with dyslipidemia, hypertension or type 2 diabetes. The member also needs a failed trial of a non-GLP-1 weight-loss drug (or intolerance to all of them), no other GLP-1 at the same time, and to meet the Virginia Medicaid Preferred Drug List requirement for the requested product. Oral GLP-1s also need a medical reason an injection will not work, or two failed injectables. Approvals last six months. A renewal needs at least 5% weight loss since the last authorization, and renewals stop once BMI falls below 25.
Source: Anthem HealthKeepers Plus VA_CAID_WeightLossMgmtPAForm.pdf (VA-BCBS-CD-019947-26). This form governs Virginia Medicaid (Anthem HealthKeepers Plus), not Virginia commercial plans.

For Virginia Medicaid members: this BMI > 40 floor is the highest BMI threshold in any Anthem document we found, and it is consistent with the Virginia Cardinal Care Medicaid thresholds documented in our Virginia Medicaid GLP-1 coverage article.

Indiana (Anthem Blue Cross and Blue Shield): directional

Indiana commercial Anthem members fall under the same Anthem clinical criteria; we confirmed that the Indiana Essential drug list links the same Wegovy and Zepbound criteria documents. Indiana Medicaid (IHCP) is a separate program with its own rules: all adult chronic-weight-management indications are excluded under 405 IAC 5-24-3(b)(1), regardless of which managed care organization the member is enrolled in (Anthem, MDwise or CareSource Indiana). An EPSDT pediatric carve-in covers members under 21 under IHCP Bulletin BT2023148. See our Indiana Medicaid GLP-1 coverage article for the primary sources.

New York (Anthem Blue Cross and Blue Shield, formerly Empire): directional

In 17 southeastern New York counties, Anthem operates as Anthem Blue Cross and Blue Shield (formerly Empire BlueCross BlueShield). Other parts of the state are served by other Blue plans, including Highmark, whose Enhanced GLP-1 policy starts at a BMI of 40. The same Anthem clinical criteria apply to commercial members, and Anthem's January 2026 formulary notice says negative formulary changes do not apply to fully insured members in New York or Connecticut.^[13] New York Medicaid (NYRx) is a separate program: New York moved its Medicaid pharmacy benefit out of managed care into the statewide NYRx fee-for-service program, which excludes GLP-1s for weight loss under 18 NYCRR § 505.3(g)(3). Confirm which drug list your commercial plan uses.

Ohio (Anthem Blue Cross and Blue Shield): directional

Ohio commercial Anthem members (Community Insurance Company, doing business as Anthem Blue Cross and Blue Shield in Ohio) fall under the same Anthem clinical criteria. Ohio Medicaid (ODM / Gainwell SPBM) is a separate program whose January 7, 2026 P&T meeting carved Wegovy back in for the MACE and MASH indications, but that applies to Ohio Medicaid, not to Anthem commercial plans. Confirm which drug list your plan uses.

Georgia (Anthem Blue Cross and Blue Shield): directional

Georgia commercial Anthem members (Blue Cross Blue Shield Healthcare Plan of Georgia) fall under the same Anthem clinical criteria. Georgia Medicaid is a separate program: Wegovy and Zepbound are absent from the May 2026 statewide Preferred Drug List, and Peach State Health Plan (a Centene plan, not Anthem) explicitly excludes weight-loss drugs. Confirm which drug list your plan uses.

CarelonRx PBM administration — what this means for prescribers and pharmacies

CarelonRx (formerly IngenioRx) is Elevance Health's wholly-owned PBM, rebranded in 2023. For most Anthem commercial members, CarelonRx is the pharmacy adjudicator at point-of-sale. Key operational points:

• PA through CarelonRx, not through Anthem Medical. For pharmacy-benefit prescriptions (the majority of GLP-1 claims), the PA request goes to CarelonRx — not to Anthem Medical. The PA forms and fax numbers on Anthem's provider portal may route to CarelonRx rather than the Anthem medical director.
• Drug list vs clinical criteria. The clinical criteria decide whether a request is medically approvable. The drug list your plan uses sets the tier, the quantity limit, any step-therapy flag, and whether weight-loss drugs are a benefit exclusion on your plan. A request can meet the criteria and still be denied if your plan excludes weight-loss drugs. Look up your plan's list at anthem.com/pharmacy-information or in the Sydney Health app.
• Quantity limits. Anthem's drug-list search shows 4 pens per 28 days for Wegovy 2.4 mg and 1 pen per week for Zepbound. Whether you can get a 90-day home-delivery fill depends on your plan's pharmacy benefit, so check before counting on one.
• Self-funded employers customize. Large employers that self-fund their benefits can instruct CarelonRx to exclude weight-management GLP-1s entirely or add coverage with different PA criteria than the standard CarelonRx commercial formulary. Your HR benefits team or the Summary Plan Description is the authoritative source for self-funded plan design.
• How to submit. Anthem says electronic prior authorization through CoverMyMeds or Surescripts is its preferred route for pharmacy requests. The fax numbers for each state are printed on the prior authorization and step-therapy exception form linked from each drug's entry in the drug list.

Appeal process — internal + external review

If Anthem or CarelonRx denies your GLP-1 PA, the standard commercial-plan appeal process applies. Key timelines and steps:

1. Request the written denial letter. The Explanation of Benefits (EOB) or denial notice must specify the clinical criterion your submission failed to satisfy — for example, “BMI documentation not provided,” “behavioral program documentation less than required duration,” or “step therapy not met.” This letter is the roadmap for your appeal.
2. File the first-level internal appeal. Commercial-plan members have the right to a first-level internal appeal. Under ACA-compliant plans, the deadline is at least 180 days from the denial date (some plans offer longer windows). Include: Letter of Medical Necessity from your prescriber, documented BMI measurement and date, comorbidity diagnoses with ICD-10 codes, behavioral program documentation (dates, provider, modalities), and — if step-therapy applies — documentation of the prior drug trial with inadequate response or contraindication.
3. Second-level internal appeal (if available). Some Anthem plans offer a two-level internal appeal. If available, escalate to the second level before requesting external review.
4. External review (IRO). If the internal appeal is denied, request an external review through an independent review organization (IRO). External review is available to all ACA-compliant commercial plans and to ERISA self-funded plans subject to applicable state law (some self-funded plans are exempt from state-mandated external review but may have contractual external review rights). External review decisions are binding on Anthem and CarelonRx.
5. State insurance department complaint. If external review rights are unavailable or exhausted, fully-insured commercial plan members can file a complaint with the state insurance commissioner in the state where the Anthem subsidiary issued the policy. Many state departments have expedited review processes for medically urgent appeals.

Use our GLP-1 PA letter generator to draft the Letter of Medical Necessity. The generator covers the standard BMI and lifestyle-program points, the cardiovascular risk-reduction pathway, and the sleep-apnea pathway.

What to do if you're denied

The most common reasons Anthem commercial GLP-1 PAs are delayed or denied — and the practical fix for each:

• Missing six-month program documentation. Anthem's criteria ask for six months in a provider-supervised program with a calorie target about 500 kcal a day below your needs, 150 minutes of exercise a week (unless you have a clinical limitation), and less than 5% weight loss despite it. “I was told to diet and exercise” is not enough. The fix: ask your prescriber for a note with the program's start date, targets, visits and your weights. If your BMI is 40 or higher, or you have class III or IV heart failure or moderate-to-severe sleep apnea, make sure the request says so, because any one of those waives the six months.
• Records older than 90 days. Anthem requires the BMI behind a first request, and the 5% weight-loss result behind a renewal, to be documented within 90 days of the request. Resubmit with a recent visit note.
• BMI documented at the wrong date or threshold. BMI must be documented on a specific date; interpolated or estimated values are rejected. The BMI documentation in the PA packet needs to come from a clinical visit note with the date, measured height and weight, and calculated BMI. Anthem asks for it within 90 days of the request.
• Employer plan exclusion. If your employer self-funds and has excluded weight-management GLP-1s, the standard internal appeal process still applies — but you are appealing a plan design decision, not a clinical decision. The fix here is typically escalating to HR and requesting an employer plan design change for the next benefits period, or pursuing cash-pay options.
• Wrong pathway for the indication. If you have had a heart attack or stroke, or you have symptomatic peripheral artery disease, Anthem's separate Wegovy cardiovascular criteria may fit better: a BMI of 27 or higher, an HbA1c below 6.5%, and current heart-protective treatment, with no six-month diet-program requirement.

While the appeal is in flight, many patients use cash-pay compounded semaglutide or tirzepatide as a bridge. For our verified telehealth provider directory, see best semaglutide providers and best tirzepatide providers.

Anthem Medicare Advantage and the CMS GLP-1 Bridge

Anthem Medicare Advantage (MA-PD) plans operate under Medicare Part D rules — which historically excluded weight-loss drugs under the statutory exclusion at 42 U.S.C. § 1395w-102(e)(2)(A). Key Medicare-specific points for Anthem MA-PD members:

• Wegovy cardiovascular pathway (now): under the March 2024 CMS HPMS guidance, Part D can cover Wegovy when it is prescribed to reduce cardiovascular risk in patients with established cardiovascular disease and a BMI of 27 or higher. Whether your Anthem MA-PD plan covers it, and on what terms, depends on the plan's formulary.
• Zepbound sleep-apnea pathway (now): Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity is not a weight-loss indication, so Part D can cover it. Coverage is plan-specific. Since January 1, 2024, Anthem Medicare Advantage has also required a verified type 2 diabetes diagnosis before approving diabetes GLP-1s such as Ozempic, and it lists weight loss as a CMS exclusion.^[16]
• CMS Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027): eligible Part D enrollees can get Wegovy (injection or tablet), Zepbound KwikPen or Foundayo for weight management with a $50 copay. Anthem's provider notice says the patient must be 18 or older, the drug must be for weight management and not available through the plan, and the patient must not have type 2 diabetes, moderate-to-severe sleep apnea or MASH, since those go through the regular Part D plan. The CMS request form asks for BMI at the start of therapy plus conditions such as prediabetes, a prior heart attack or stroke, peripheral artery disease, heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease, and CMS makes the final call. Because the Bridge runs outside the Part D benefit, CMS says the Part D deductible does not apply, none of the $50 copay counts toward your Part D out-of-pocket total, and Extra Help (the low-income subsidy) does not reduce it. Saxenda is not included.^[7][15][17]

Anthem Medicare Advantage members who are denied a GLP-1 PA have the right to a Medicare Part C/D coverage determination, redetermination, reconsideration (through the Qualified Independent Contractor), and ALJ hearing under the standard Medicare appeals framework. See our Medicare Part D coverage guide for the full appeal chain. Every Part D carrier uses this ladder, and Humana's version of it is laid out step by step for Humana members.

Excluded plans — Anthem Medicaid

Anthem's Medicaid plans follow each state's rules and Preferred Drug List, not Anthem's commercial criteria. Coverage for GLP-1 weight-loss drugs varies dramatically by state:

• Virginia Medicaid (Anthem HealthKeepers Plus): BMI > 40, or BMI > 37 with dyslipidemia, hypertension or type 2 diabetes, plus a failed non-GLP-1 weight-loss drug and six-month approvals (September 2026 form, summarized above).
• California Medi-Cal (Anthem Blue Cross): weight-loss GLP-1s were removed on January 1, 2026. Requests are still considered for Wegovy for MASH or cardiovascular disease and for Zepbound for sleep apnea (notice summarized above).
• Georgia Medicaid (Anthem Georgia): Wegovy and Zepbound are absent from the statewide Preferred Drug List. See our Georgia Medicaid GLP-1 coverage article.
• Indiana Medicaid (Anthem Indiana Medicaid): Weight-loss GLP-1s excluded for adults under 405 IAC 5-24-3(b)(1); EPSDT pediatric carve-in for under-21. See our Indiana Medicaid GLP-1 coverage article.
• Other states: coverage varies. Check your specific state Medicaid PDL before filing any Anthem Medicaid GLP-1 PA.

Anthem vs Aetna vs Cigna — commercial PA guide comparison

This article is the third in the commercial-insurer PA guide triplet (Aetna → Cigna → Anthem). Key comparison points:

For the Aetna detail, see our Aetna GLP-1 PA guide. For the Cigna detail, see our Cigna GLP-1 PA guide. For the UnitedHealthcare detail (the largest commercial insurer), see our UHC GLP-1 PA guide — CDG CS10028.1, OptumRx January 2025 Wegovy-preferred formulary update, CDG CS10191 for Foundayo, NY + MA state mandate overrides, and the UHC Medicare Advantage GLP-1 Bridge. For federal employees and retirees on the BCBS Federal Employee Program, see our BCBS FEP GLP-1 PA guide — FEP is structurally distinct from all local BCBS state plans and from Anthem/Elevance Health: OPM contract authority, dedicated CVS Caremark FEP formulary, single national formulary, and federal disputed-claims appeals pathway through OPM rather than a state IRO. The commercial PA quintet is now complete.

Anthem vs state Medicaid — commercial payer parallel

Anthem operates as both a commercial insurer (the 14-state Blue Cross licensee) AND a Medicaid managed care organization in 10+ states. This dual role means the same Anthem brand can mean radically different GLP-1 coverage depending on whether a member is on a commercial plan or a Medicaid plan.

The commercial PA guide triplet (Aetna + Cigna + Anthem) mirrors the architecture of our state Medicaid coverage articles — both document the primary-source PA criteria from the largest payers in each segment. Key structural differences:

• Commercial plans (Anthem criteria approved by CarelonRx P&T): BMI 30 or higher, or 27 or higher with a weight-related condition, six months in a supervised program (with three medical exceptions), and 5% weight loss to renew. Coverage also depends on whether your plan includes weight-loss drugs.
• Medicaid plans (state PDLs): criteria range from exclusion (Indiana and Georgia, for all adults) to the Virginia BMI > 40 floor to California, where only non-weight-loss uses (MASH, cardiovascular disease, sleep apnea) are still reviewed. Driven by state budget decisions and CMS optional-benefit rules under 42 U.S.C. § 1396r-8(d)(2)(A).
• Medicare Advantage (CMS Bridge): from July 1, 2026, the Bridge offers a $50 copay path for eligible Part D enrollees who do not have type 2 diabetes, sleep apnea or MASH. CMS decides eligibility.

For the full 20-state Medicaid series, start with our GLP-1 insurance coverage: Medicare, Medicaid, and commercial overview.

Further reading

• Top GLP-1 insurance-coverage questions on Reddit, answered
• GLP-1 contraindications cheat sheet